We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Ironwood Pharmaceuticals (IRWD - Free Report) . Shares have lost about 13.9% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Ironwood due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.
Ironwood’s Q4 Earnings and Revenues Fall Shy of Estimates
Ironwood reported an adjusted loss of 1 cent per share for the fourth quarter of 2025 against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported adjusted earnings of 1 cent per share in the year-ago quarter.
Total revenues in the fourth quarter were $47.7 million, which also missed the Zacks Consensus Estimate of $53 million. Revenues decreased by around 47.3% year over year.
Quarter in Detail
As reported by its partner AbbVie, Ironwood’s marketed product, Linzess, generated net sales of $163.2 million in the United States, down 27% year over year, due to rebate timing issues and higher pricing pressure from the Medicare Part D redesign.
Total prescription demand for Linzess increased 13% year over year during the fourth quarter.
Ironwood’s share of net profit from the sales of Linzess in the United States (included in collaborative revenues) totaled $45.2 million, reflecting a decline of 49% year over year.
Ironwood's royalties and other revenues were $2.5 million in the fourth quarter. In the year-ago quarter, the company recorded $2.1 million in royalties and other revenues.
Total cost and expenses (including research and development expenses, selling, general and administrative expenses and restructuring expenses) in the fourth quarter were $40.9 million, down 30.8% from the year-ago quarter.
Ironwood recorded adjusted EBITDA of $10.9 million in the fourth quarter, reflecting a 70.7% decrease year over year.
As of Dec. 31, 2025, Ironwood had cash and cash equivalents worth $215.5 million compared with $140.4 million as of Sept. 30, 2025.
2026 Guidance
Ironwood reiterated its full-year 2026 revenue guidance, which it had provided in January 2026.
The company continues to expect total revenues of $450 million to $475 million in 2026.
U.S. sales of Linzess (to be recorded by AbbVie) are expected to be in the range of $1.13-$1.18 billion in 2026.
The company expects to deliver an adjusted EBITDA of more than $300 million in 2026, indicating effective cost management.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
VGM Scores
At this time, Ironwood has a nice Growth Score of B, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Ironwood has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Ironwood is part of the Zacks Medical - Drugs industry. Over the past month, Summit Therapeutics PLC (SMMT - Free Report) , a stock from the same industry, has gained 9.2%. The company reported its results for the quarter ended December 2025 more than a month ago.
Summit Therapeutics reported revenues of $0 million in the last reported quarter, representing a year-over-year change of -100%. EPS of -$0.29 for the same period compares with -$0.08 a year ago.
Summit Therapeutics is expected to post a loss of $0.30 per share for the current quarter, representing a year-over-year change of -233.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Summit Therapeutics. Also, the stock has a VGM Score of F.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
It has been about a month since the last earnings report for Ironwood Pharmaceuticals (IRWD - Free Report) . Shares have lost about 13.9% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Ironwood due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.
Ironwood’s Q4 Earnings and Revenues Fall Shy of Estimates
Ironwood reported an adjusted loss of 1 cent per share for the fourth quarter of 2025 against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported adjusted earnings of 1 cent per share in the year-ago quarter.
Total revenues in the fourth quarter were $47.7 million, which also missed the Zacks Consensus Estimate of $53 million. Revenues decreased by around 47.3% year over year.
Quarter in Detail
As reported by its partner AbbVie, Ironwood’s marketed product, Linzess, generated net sales of $163.2 million in the United States, down 27% year over year, due to rebate timing issues and higher pricing pressure from the Medicare Part D redesign.
Total prescription demand for Linzess increased 13% year over year during the fourth quarter.
Ironwood’s share of net profit from the sales of Linzess in the United States (included in collaborative revenues) totaled $45.2 million, reflecting a decline of 49% year over year.
Ironwood's royalties and other revenues were $2.5 million in the fourth quarter. In the year-ago quarter, the company recorded $2.1 million in royalties and other revenues.
Total cost and expenses (including research and development expenses, selling, general and administrative expenses and restructuring expenses) in the fourth quarter were $40.9 million, down 30.8% from the year-ago quarter.
Ironwood recorded adjusted EBITDA of $10.9 million in the fourth quarter, reflecting a 70.7% decrease year over year.
As of Dec. 31, 2025, Ironwood had cash and cash equivalents worth $215.5 million compared with $140.4 million as of Sept. 30, 2025.
2026 Guidance
Ironwood reiterated its full-year 2026 revenue guidance, which it had provided in January 2026.
The company continues to expect total revenues of $450 million to $475 million in 2026.
U.S. sales of Linzess (to be recorded by AbbVie) are expected to be in the range of $1.13-$1.18 billion in 2026.
The company expects to deliver an adjusted EBITDA of more than $300 million in 2026, indicating effective cost management.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
VGM Scores
At this time, Ironwood has a nice Growth Score of B, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Ironwood has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Ironwood is part of the Zacks Medical - Drugs industry. Over the past month, Summit Therapeutics PLC (SMMT - Free Report) , a stock from the same industry, has gained 9.2%. The company reported its results for the quarter ended December 2025 more than a month ago.
Summit Therapeutics reported revenues of $0 million in the last reported quarter, representing a year-over-year change of -100%. EPS of -$0.29 for the same period compares with -$0.08 a year ago.
Summit Therapeutics is expected to post a loss of $0.30 per share for the current quarter, representing a year-over-year change of -233.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Summit Therapeutics. Also, the stock has a VGM Score of F.